Analysts' ratings for Gilead Sciences GILD over the last quarter vary from bullish to bearish, as provided by 22 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 10 | 10 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 2 | 0 | 0 |
| 3M Ago | 1 | 7 | 8 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of $99.32, a high estimate of $125.00, and a low estimate of $80.00. This current average reflects an increase of 14.23% from the previous average price target of $86.95.
Interpreting Analyst Ratings: A Closer Look
In examining recent analyst actions, we gain insights into how financial experts perceive Gilead Sciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Chris Schott | JP Morgan | Raises | Overweight | $115.00 | $105.00 |
| Matthew Harrison | Morgan Stanley | Raises | Overweight | $113.00 | $87.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Neutral | $80.00 | $80.00 |
| Brian Abrahams | RBC Capital | Maintains | Sector Perform | $84.00 | $84.00 |
| Matthew Biegler | Oppenheimer | Raises | Outperform | $115.00 | $105.00 |
| Tim Anderson | B of A Securities | Announces | Buy | $109.00 | - |
| Colin Bristow | UBS | Raises | Neutral | $96.00 | $70.00 |
| Salim Syed | Mizuho | Raises | Outperform | $100.00 | $90.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $84.00 | $81.00 |
| Alexandria Hammond | Wolfe Research | Announces | Outperform | $110.00 | - |
| Geoff Meacham | Citigroup | Announces | Buy | $125.00 | - |
| Asthika Goonewardene | Truist Securities | Raises | Hold | $97.00 | $83.00 |
| Hartaj Singh | Oppenheimer | Raises | Outperform | $105.00 | $95.00 |
| Evan Seigerman | BMO Capital | Raises | Outperform | $102.00 | $94.00 |
| Brian Skorney | Baird | Raises | Neutral | $95.00 | $80.00 |
| Chris Schott | JP Morgan | Raises | Overweight | $105.00 | $100.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $81.00 | $75.00 |
| Salveen Richter | Goldman Sachs | Raises | Neutral | $84.00 | $74.00 |
| Olivia Brayer | Cantor Fitzgerald | Raises | Neutral | $80.00 | $70.00 |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $105.00 | $100.00 |
| Carter Gould | Barclays | Raises | Equal-Weight | $95.00 | $84.00 |
| Joseph Catanzaro | Piper Sandler | Raises | Overweight | $105.00 | $95.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Gilead Sciences. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Gilead Sciences compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Gilead Sciences's stock. This analysis reveals shifts in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Gilead Sciences's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Gilead Sciences analyst ratings.
Unveiling the Story Behind Gilead Sciences
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Key Indicators: Gilead Sciences's Financial Health
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Gilead Sciences showcased positive performance, achieving a revenue growth rate of 7.02% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Gilead Sciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.61%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Gilead Sciences's ROE excels beyond industry benchmarks, reaching 6.82%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Gilead Sciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.32% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.26.
The Basics of Analyst Ratings
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
